If signs or symptoms of congestive heart failure occur during therapy, discontinue use. When drug was given to animals, negative inotropic effects were noted. Do not use for other indications in patients with evidence of ventricular dysfunction unless benefit clearly outweighs risk. Inform patients of signs and symptoms of congestive heart failure, treat with caution, and monitor for signs and symptoms of congestive heart failure during therapy. However, these findings were not seen in mice.
Clinical relevance is unknown.
Contraindicated for treatment of onychomycosis in pregnant patients or women contemplating pregnancy. HIV-infected women should not breastfeed. No pharmacokinetic data are available. Long-term effects of therapy on bone growth are unknown. Other reactions reported with postmarketing experience using capsules included peripheral edema, allergic reactions, including rash, pruritus, urticaria, angioedema, elevated liver enzymes and, rarely, anaphylaxis, liver failure, and Stevens-Johnson syndrome.